tranexamic acid has been researched along with von Willebrand Diseases in 42 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
von Willebrand Diseases: Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 9.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| "Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 7.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
| "To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 7.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
| "Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 7.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 5.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| " Prophylaxis (Desmopressin, clotting factor concentrates or tranexamic acid) to prevent bleeding was described in 100% (30/30) of EA procedures and in 4% (24/661) of hysterectomies." | 5.41 | Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. ( Bongers, MY; Eising, HP; Leemans, JC; Punt, MC, 2023) |
| " Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 5.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
| " The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders." | 4.98 | Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018) |
| "8%) had menorrhagia, for which combined oral contraceptives, tranexamic acid and desmopressin were the most common first-line therapies for menorrhagia, whereas VWF was third-line therapy reported in 13 women (1." | 4.93 | Von Willebrand factor for menorrhagia: a survey and literature review. ( Brambilla, DJ; James, AH; Kessler, CM; Konkle, BA; Kouides, PA; Machin, N; Malec, LM; Neff, AT; Philipp, CS; Ragni, MV, 2016) |
| "Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 3.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
| "To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 3.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
| "Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 3.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
| "The most common form of BDs is von Willebrand Disease, reflecting 13% of adolescents with AUB." | 2.58 | Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders. ( Deligeoroglou, E; Karountzos, V, 2018) |
| "In vWD, the treatment of menorrhagia is usually medical, but there is lack of prospective data on the efficacy of commonly used medical therapies in these women." | 2.43 | Women and von Willebrand disease: controversies in diagnosis and management. ( Chi, C; Kadir, RA, 2006) |
| "Tranexamic acid was usually added for mucosal surgery." | 2.41 | Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. ( Griffioen, A; Harrington, C; Lee, CA; Nitu-Whalley, IC, 2001) |
| "Peri-procedural management of von Willebrand disease (VWD) utilizes von Willebrand factor (VWF) concentrates or desmopressin (DDAVP) to increase VWF levels." | 1.91 | Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes. ( Chandrakumaran, P; Hews-Girard, J; Poon, MC, 2023) |
| "Our review of the literature and the results of the survey showed considerable heterogeneity in treatment regimens, and a lack of consistency in reporting of the variables that determine factor concentrate dosing and monitoring." | 1.43 | Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. ( Altisent, C; Dolan, G; Katsarou, O; López Fernández, MF; Windyga, J; Zülfikar, B, 2016) |
| "We have analyzed the databases for von Willebrand disease (VWD) from the hemophilia center for adult patients with bleeding disorders in South Australia." | 1.37 | Diagnosis and management of adult patients with von Willebrand disease in South Australia. ( Duncan, EM; Lloyd, JV; Mangos, HM; McRae, SJ; Rodgers, SE, 2011) |
| "Hemophilia A and B and von Willebrand disease (VWD) belong to the most frequent congenital coagulation disorders and are a significant problem in patients who require periodontal therapy or tooth extraction." | 1.36 | Comprehensive treatment of periodontitis in patients with von Willebrand disease. ( Alesci, S; Eickholz, P; Miesbach, W; Nickles, K; Wohlfeil, M, 2010) |
| " Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 1.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
| "A 42-year-old female with von Willebrand's disease was managed with desmopressin and tranexamic acid to aid haemostasis following a vaginal hysterectomy." | 1.31 | Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. ( Bertholini, DM; Butler, CS, 2000) |
| "A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel." | 1.31 | Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. ( Meijer, K; Peters, FT; van der Meer, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.14) | 18.7374 |
| 1990's | 6 (14.29) | 18.2507 |
| 2000's | 11 (26.19) | 29.6817 |
| 2010's | 16 (38.10) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Brignardello-Petersen, R | 2 |
| El Alayli, A | 2 |
| Husainat, N | 2 |
| Kalot, M | 1 |
| Shahid, S | 2 |
| Aljabirii, Y | 2 |
| Britt, A | 2 |
| Alturkmani, H | 2 |
| El-Khechen, H | 2 |
| Motaghi, S | 2 |
| Roller, J | 2 |
| Dimassi, A | 1 |
| Abughanimeh, O | 1 |
| Madoukh, B | 1 |
| Arapshian, A | 1 |
| Grow, JM | 1 |
| Kouides, P | 3 |
| Laffan, M | 1 |
| Leebeek, FWG | 1 |
| O'Brien, SH | 1 |
| Tosetto, A | 2 |
| James, PD | 2 |
| Connell, NT | 2 |
| Flood, V | 1 |
| Mustafa, RA | 2 |
| Kalot, MA | 1 |
| Abdul-Kadir, R | 1 |
| Couper, S | 1 |
| Lavin, M | 3 |
| Ozelo, MC | 1 |
| Weyand, A | 1 |
| Flood, VH | 1 |
| Chandrakumaran, P | 1 |
| Hews-Girard, J | 1 |
| Poon, MC | 1 |
| Ragni, MV | 2 |
| Rothenberger, SD | 1 |
| Feldman, R | 1 |
| Nance, D | 1 |
| Leavitt, AD | 1 |
| Malec, L | 1 |
| Kulkarni, R | 1 |
| Sidonio, R | 1 |
| Kraut, E | 1 |
| Lasky, J | 1 |
| Pruthi, R | 1 |
| Angelini, D | 1 |
| Philipp, C | 1 |
| Hwang, N | 1 |
| Wheeler, AP | 1 |
| Seaman, C | 1 |
| Machin, N | 2 |
| Xavier, F | 1 |
| Meyer, M | 1 |
| Bellissimo, D | 1 |
| Humphreys, G | 1 |
| Smith, KJ | 1 |
| Merricks, EP | 1 |
| Nichols, TC | 1 |
| Ivanco, D | 1 |
| Vehec, D | 1 |
| Koerbel, G | 1 |
| Althouse, AD | 1 |
| Eising, HP | 1 |
| Punt, MC | 1 |
| Leemans, JC | 1 |
| Bongers, MY | 1 |
| Lasry, A | 1 |
| Gil, Y | 1 |
| Balayla, J | 1 |
| Scott, M | 1 |
| Hay, CRM | 1 |
| Elkhalifa, S | 1 |
| Tower, C | 1 |
| Cocker, M | 1 |
| Thachil, J | 1 |
| Deligeoroglou, E | 1 |
| Karountzos, V | 1 |
| Lewandowski, B | 1 |
| Wojnar, J | 1 |
| Brodowski, R | 1 |
| Mucha, M | 1 |
| Czenczek-Lewandowska, E | 1 |
| Brzęcka, D | 1 |
| Bannow, BS | 1 |
| Konkle, BA | 2 |
| Tiede, A | 2 |
| van Galen, KP | 1 |
| Engelen, ET | 1 |
| Mauser-Bunschoten, EP | 1 |
| van Es, RJ | 1 |
| Schutgens, RE | 1 |
| Malec, LM | 1 |
| James, AH | 1 |
| Kessler, CM | 1 |
| Kouides, PA | 1 |
| Neff, AT | 1 |
| Philipp, CS | 1 |
| Brambilla, DJ | 1 |
| Appelmann, I | 1 |
| Kreher, S | 1 |
| Parmentier, S | 1 |
| Wolf, HH | 1 |
| Bisping, G | 1 |
| Kirschner, M | 1 |
| Bergmann, F | 1 |
| Schilling, K | 1 |
| Brümmendorf, TH | 1 |
| Petrides, PE | 1 |
| Matzdorff, A | 1 |
| Griesshammer, M | 1 |
| Riess, H | 1 |
| Koschmieder, S | 1 |
| Windyga, J | 1 |
| Dolan, G | 1 |
| Altisent, C | 1 |
| Katsarou, O | 1 |
| López Fernández, MF | 1 |
| Zülfikar, B | 1 |
| Eghbali, A | 1 |
| Melikof, L | 1 |
| Taherahmadi, H | 1 |
| Bagheri, B | 1 |
| Sánchez-Luceros, A | 1 |
| Woods, AI | 1 |
| Bermejo, E | 1 |
| Shukla, S | 1 |
| Acharya, S | 1 |
| Rydz, N | 1 |
| Othman, M | 1 |
| O'Donnell, JS | 1 |
| Nickles, K | 1 |
| Wohlfeil, M | 1 |
| Alesci, S | 1 |
| Miesbach, W | 1 |
| Eickholz, P | 1 |
| Mikhail, S | 1 |
| Rodgers, SE | 1 |
| Lloyd, JV | 1 |
| Mangos, HM | 1 |
| Duncan, EM | 1 |
| McRae, SJ | 1 |
| Nair, SC | 1 |
| Viswabandya, A | 1 |
| Srivastava, A | 2 |
| Jiménez-Yuste, V | 1 |
| Prim, MP | 1 |
| De Diego, JI | 1 |
| Villar, A | 1 |
| Quintana, M | 1 |
| Rabanal, I | 1 |
| Sastre, N | 1 |
| Hernández-Navarro, F | 1 |
| Mohri, H | 1 |
| Mannucci, PM | 2 |
| Morimoto, Y | 1 |
| Yoshioka, A | 1 |
| Sugimoto, M | 1 |
| Imai, Y | 1 |
| Kirita, T | 1 |
| Kadir, RA | 1 |
| Chi, C | 1 |
| Castaman, G | 1 |
| Rodeghiero, F | 1 |
| Cappelletti, A | 1 |
| Baudo, F | 1 |
| Eikenboom, JC | 2 |
| Federici, AB | 2 |
| Lethagen, S | 1 |
| Linari, S | 1 |
| Lusher, J | 1 |
| Nishino, M | 1 |
| Petrini, P | 1 |
| Ungerstedt, JS | 1 |
| Jackson, N | 1 |
| Hashim, ZA | 1 |
| Zainal, NA | 1 |
| Jamaluddin, N | 1 |
| Prinsley, P | 1 |
| Wood, M | 1 |
| Lee, CA | 2 |
| Ong, YL | 1 |
| Hull, DR | 1 |
| Mayne, EE | 1 |
| Onundarson, PT | 1 |
| Baerlocher, GM | 1 |
| Leoncini-Franscini, L | 1 |
| Wuillemin, WA | 1 |
| Furlan, M | 1 |
| Sacco, R | 1 |
| Stabile, F | 1 |
| Carpenedo, M | 1 |
| Zingaro, E | 1 |
| Bertholini, DM | 1 |
| Butler, CS | 1 |
| Nitu-Whalley, IC | 1 |
| Griffioen, A | 1 |
| Harrington, C | 1 |
| Stubbs, M | 1 |
| Lloyd, J | 1 |
| Meijer, K | 1 |
| Peters, FT | 1 |
| van der Meer, J | 1 |
| Nilsson, IM | 1 |
| Mikaelsson, M | 1 |
| Vilhardt, H | 1 |
| Walter, H | 1 |
| van der Meer, FJ | 1 |
| Briët, E | 1 |
| Pignanelli, M | 1 |
| Rota, L | 1 |
| Pignanelli, C | 1 |
| Vinckier, F | 1 |
| Vermylen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study[NCT02606045] | Phase 3 | 60 participants (Anticipated) | Interventional | 2019-02-07 | Active, not recruiting | ||
| National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042] | 1,100 participants (Anticipated) | Observational | 2007-07-31 | Completed | |||
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
12 reviews available for tranexamic acid and von Willebrand Diseases
| Article | Year |
|---|---|
Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.
Topics: Factor VIII; Hemostasis; Humans; Tranexamic Acid; von Willebrand Diseases; von Willebrand Factor | 2022 |
Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review.
Topics: Female; Hemorrhage; Humans; Menorrhagia; Prospective Studies; Tranexamic Acid; von Willebrand Diseas | 2023 |
Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders.
Topics: Adolescent; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Female; Humans; Menorrhagia; Me | 2018 |
Inherited Bleeding Disorders in the Obstetric Patient.
Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia | 2018 |
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia | 2015 |
Von Willebrand factor for menorrhagia: a survey and literature review.
Topics: Antifibrinolytic Agents; Contraceptives, Oral; Databases, Factual; Deamino Arginine Vasopressin; Fem | 2016 |
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis
Topics: Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transf | 2016 |
New treatment approaches to von Willebrand disease.
Topics: Deamino Arginine Vasopressin; Hemorrhage; Humans; Tranexamic Acid; von Willebrand Diseases; von Will | 2016 |
Diagnosis and management of von Willebrand disease: a developing country perspective.
Topics: Clinical Laboratory Techniques; Coagulants; Deamino Arginine Vasopressin; Developing Countries; Fact | 2011 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Women and von Willebrand disease: controversies in diagnosis and management.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Contraceptives, Oral, Synthetic; Deamino Arginine Vasopr | 2006 |
Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
Topics: Anesthesia, Obstetrical; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Deamino Ar | 2001 |
2 trials available for tranexamic acid and von Willebrand Diseases
| Article | Year |
|---|---|
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Topics: Adolescent; Adult; Cross-Over Studies; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Tranexa | 2023 |
Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine Vasopressin; D | 2000 |
28 other studies available for tranexamic acid and von Willebrand Diseases
| Article | Year |
|---|---|
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
Topics: Female; Humans; Menorrhagia; Postpartum Hemorrhage; Pregnancy; Systematic Reviews as Topic; Tranexam | 2022 |
Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
Topics: Adolescent; Adult; Deamino Arginine Vasopressin; Factor VIII; Hemorrhage; Humans; Retrospective Stud | 2023 |
Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts.
Topics: Adult; Cysts; Female; Hemorrhage; Humans; Ovulation; Pain; Pelvic Pain; Tranexamic Acid; Treatment O | 2020 |
Management of pregnancy in type 3 von Willebrand disease with alloantibodies.
Topics: Adult; Disease Management; Factor VIIa; Female; Humans; Isoantibodies; Platelet Transfusion; Pregnan | 2018 |
Dental extractions in patients with mild hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Dental Caries; Female; Hemop | 2018 |
Diagnosis and treatment of acquired von Willebrand syndrome.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine V | 2012 |
Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Coagulants; Databases, Factual; Dose-Response Rel | 2016 |
Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial.
Topics: Antifibrinolytic Agents; Child, Preschool; Controlled Before-After Studies; Double-Blind Method; Fem | 2016 |
PT-VWD posing diagnostic and therapeutic challenges - small case series.
Topics: Adolescent; Child, Preschool; Deamino Arginine Vasopressin; Drug Therapy, Combination; Factor VIIa; | 2017 |
Comprehensive treatment of periodontitis in patients with von Willebrand disease.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Anti-Bacterial Agents; Chron | 2010 |
von Willebrand disease in the pediatric and adolescent population.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Contusions; Deamino Arginine Vasopres | 2010 |
Diagnosis and management of adult patients with von Willebrand disease in South Australia.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Databases, Factual; Deamino Arginine Vasopr | 2011 |
Otolaryngologic surgery in children with von Willebrand disease.
Topics: Adenoidectomy; Adolescent; Antifibrinolytic Agents; Child; Child, Preschool; Deamino Arginine Vasopr | 2002 |
High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2002 |
Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Chronically Ill; Factor VIII | 2005 |
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; Child, Preschool; Deamino Arginine Vasopressin | 2006 |
Puerperal acquired factor VIII inhibitor causing a von Willebrand-like syndrome in a patient with anti-DNA antibodies.
Topics: Adult; Antibodies, Antinuclear; Factor VIII; Female; Gingival Hemorrhage; Humans; Lupus Erythematosu | 1995 |
Adenotonsillectomy in patients with inherited bleeding disorders.
Topics: Adenoidectomy; Blood Coagulation Disorders; Child; Child, Preschool; Deamino Arginine Vasopressin; F | 1993 |
Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Drug Administration Schedule; Fema | 1998 |
Treatment of menorrhagia in von Willebrand's disease.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid; von Willebrand Disease | 1999 |
[Patient with recurrent gastrointestinal hemorrhage in acquired von Willebrand disease].
Topics: Autoantibodies; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Recurrence; Tranexamic Aci | 1999 |
Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease.
Topics: Acute Disease; Adult; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Hyponatremia; Hyste | 2000 |
A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Clinical Protocols; Deamino Arginine Vasopressin; | 2001 |
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogen | 2001 |
DDAVP factor VIII concentrate and its properties in vivo and in vitro.
Topics: Adolescent; Aged; Arginine Vasopressin; Blood Coagulation; Blood Donors; Child; Deamino Arginine Vas | 1979 |
Acquired von Willebrand's disease due to excessive fibrinolysis.
Topics: Blood Coagulation Disorders; Fibrinolysis; Hemorrhagic Disorders; Humans; Male; Middle Aged; Tranexa | 1992 |
[Extractions in hemophilic patients. Control of hemostasis with DDAVP].
Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophilia A; Hemo | 1988 |
Dental extractions in hemophilia: reflections on 10 years' experience.
Topics: Aminocaproic Acid; Bandages; Cellulose, Oxidized; Dental Care for Disabled; Factor IX; Factor VIII; | 1985 |